IL87740A - Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same - Google Patents

Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same

Info

Publication number
IL87740A
IL87740A IL87740A IL8774088A IL87740A IL 87740 A IL87740 A IL 87740A IL 87740 A IL87740 A IL 87740A IL 8774088 A IL8774088 A IL 8774088A IL 87740 A IL87740 A IL 87740A
Authority
IL
Israel
Prior art keywords
same
diagnostic
antibody conjugates
methods
glycosyl
Prior art date
Application number
IL87740A
Other languages
English (en)
Other versions
IL87740A0 (en
Original Assignee
Molecular Medicine Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Medicine Center filed Critical Molecular Medicine Center
Publication of IL87740A0 publication Critical patent/IL87740A0/xx
Publication of IL87740A publication Critical patent/IL87740A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL87740A 1987-09-14 1988-09-14 Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same IL87740A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/096,615 US4859449A (en) 1987-09-14 1987-09-14 Modified antibodies for enhanced hepatocyte clearance

Publications (2)

Publication Number Publication Date
IL87740A0 IL87740A0 (en) 1989-02-28
IL87740A true IL87740A (en) 1993-06-10

Family

ID=22258228

Family Applications (1)

Application Number Title Priority Date Filing Date
IL87740A IL87740A (en) 1987-09-14 1988-09-14 Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same

Country Status (9)

Country Link
US (1) US4859449A (xx)
EP (1) EP0308208B1 (xx)
JP (1) JP2519305B2 (xx)
AT (1) ATE97817T1 (xx)
AU (1) AU611196B2 (xx)
CA (1) CA1310264C (xx)
DE (1) DE3885987T2 (xx)
IE (1) IE62005B1 (xx)
IL (1) IL87740A (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
AU601536B2 (en) * 1986-12-30 1990-09-13 Nihon Medi-Physics Co., Ltd. High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilization
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5241052A (en) * 1988-03-04 1993-08-31 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
US5308604A (en) * 1989-04-19 1994-05-03 Deutsches Krebsforschungsinstitut Conjugates for tumor localization and/or tumor therapy
ATE136224T1 (de) * 1989-09-29 1996-04-15 Neorx Corp Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5130129A (en) * 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
DK176290D0 (da) * 1990-07-24 1990-07-24 Novo Nordisk As Terapeutisk og diagnostisk praeparat
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5099005A (en) * 1990-09-28 1992-03-24 Neorx Corporation Method of enhancing immunoglobulin fragment production
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
AU4288493A (en) * 1992-05-15 1993-12-13 Mallinckrodt Medical, Inc. Method of preparing a diagnostic agent for detecting inflammations
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
US7318921B2 (en) 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AU742626B2 (en) * 1998-05-20 2002-01-10 Immunomedics Inc. Therapeutics using a bispecific anti-HLA class II invariant chain X anti-pathogen antibody
WO1999065523A1 (en) 1998-06-15 1999-12-23 Altarex Corp. Immunotherapeutic composition and method for the treatment of prostate cancer
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6383812B1 (en) 1999-05-28 2002-05-07 Academia Sinica Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins
US6564084B2 (en) * 2001-03-02 2003-05-13 Draeger Medical, Inc. Magnetic field shielding and detecting device and method thereof
WO2002100334A2 (en) * 2001-06-11 2002-12-19 University Of Miami Use of radiopharmaceutical complexes in achieving transplantation tolerance
EP1438387A4 (en) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
EP1499347A2 (en) * 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
WO2004033667A2 (en) * 2002-10-10 2004-04-22 Department Of Veterans Affairs Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
WO2004043407A2 (en) * 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
US8004662B2 (en) * 2004-10-15 2011-08-23 Malvern Instruments Incorporated Pharmaceutical mixture evaluation
US20060234934A1 (en) * 2005-04-15 2006-10-19 Kilmon Joseph A Composition and Method for Selective Cytostasis
PL1928503T3 (pl) 2005-08-24 2012-12-31 Immunogen Inc Sposób wytwarzania koniugatów majtazynoid-przeciwciało
WO2007070680A2 (en) * 2005-12-16 2007-06-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Optically detectable probes for identification and treatment of tumors
WO2009041037A1 (ja) * 2007-09-26 2009-04-02 Japan As Represented By The President Of National Cardiovascular Center 体内に存在する病因物質の低下剤
WO2010011284A2 (en) 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
LT2437790T (lt) 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
JP2013516967A (ja) * 2010-01-14 2013-05-16 グラクソ グループ リミテッド 肝臓標的化ドメイン抗体
CN102869784A (zh) 2010-04-07 2013-01-09 动量制药公司 高甘露糖聚糖
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012066896A1 (ja) * 2010-11-19 2012-05-24 Kato Junji 組合わせ医薬製剤
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
MX369659B (es) 2011-03-29 2019-11-15 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
ATE61000T1 (de) * 1983-07-29 1991-03-15 Milton David Goldenberg Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.

Also Published As

Publication number Publication date
IE62005B1 (en) 1994-12-14
AU2223988A (en) 1989-03-16
EP0308208A1 (en) 1989-03-22
DE3885987D1 (de) 1994-01-13
US4859449A (en) 1989-08-22
DE3885987T2 (de) 1994-06-09
IL87740A0 (en) 1989-02-28
CA1310264C (en) 1992-11-17
ATE97817T1 (de) 1993-12-15
JPH01221400A (ja) 1989-09-04
EP0308208B1 (en) 1993-12-01
AU611196B2 (en) 1991-06-06
IE882775L (en) 1989-03-14
JP2519305B2 (ja) 1996-07-31

Similar Documents

Publication Publication Date Title
IL87740A (en) Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same
Folli et al. Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
KR100361075B1 (ko) 리셉터조절제및그와관련된방법
JPH06500563A (ja) 調節された浄化時間を有する修飾抗体
JPH03500419A (ja) 多特異抗白血球結合体及び哺乳動物用非経口的注射剤
ATE279946T1 (de) Herstellung und verwendung von immunkonjugaten die eine vl-kette enthalten welche am asn in position 18 glykosyliert ist
JPH02152956A (ja) 隣接基放射性金属キレート生成化合物
US5059413A (en) Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
WO1992019213A3 (en) Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
DE69535094T2 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
KR20060096272A (ko) 글리코펩타이드 조성물
Pimm et al. Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody
SE8602743L (sv) Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid
EP0525119A4 (en) Antibody conjugates for treatment of neoplastic disease
EP0173663A3 (en) The use of a specific tumor associated antigen, sialosyllactotetraose, in diagnostic or therapeutic procedures related to cancer deseases
JPH04506343A (ja) ターゲッティング薬剤
Chen et al. Extracorporeal immunoadsorption compared to avidin chase: Enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96
Hurwitz et al. Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
Ohkawa et al. Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines
JPH05500953A (ja) 免疫共役体およびその代謝物の非標的保持量を減少させる方法
WO1990011779A1 (en) Heteroconjugates
Yamaguchi et al. In vivo efficacy of neocarzinostatin coupled with Fab human/mouse chimeric monoclonal antibody A7 against human colorectal cancer
Yoneda et al. Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees